NEW UPDATE ON GUIDELINES FOR PREDICTIVE BIOMARKERS IN NON-SMALL CELL LUNG CANCER (NSCLCP)

Non-small cell lung cancer (NSCLC) has the largest number of identified therapeutic targets, some of which have therapeutic utility. The use of next-generation sequencing facilitates accurate molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and biomarkers predictive of response to immunotherapy. In this consensus, a group of experts …

NEW UPDATE ON GUIDELINES FOR PREDICTIVE BIOMARKERS IN NON-SMALL CELL LUNG CANCER (NSCLCP) Read More »